Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VRC07-523LS
- Development stage
- Phase 2
- Lead developer
- Vaccine Research Center
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (iv), Subcutaneous (sc), Intramuscular (im)
01
Overview
VRC07-523LS is a second-generation broadly neutralizing monoclonal antibody (bnAb) that targets the CD4 binding site on the HIV envelope glycoprotein gp120. It has broad and potent neutralizing activity against approximately 96% of HIV strains. This antibody is designed to be more potent and have a longer half-life compared to its predecessor, VRC01, making it suitable for long-acting HIV prevention and treatment strategies.
- Other names
- VRC-HIVMAB075-00-ABVRC-HIVMAB-075-00-ABVRC-HIVMAB 075-00-ABvrc07-523lsvrc-07-523lsvrc 07-523ls
02
Targets
Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on VRC07-523LS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VRC07-523LS.